Cargando…
Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial
The aim of the study was to demonstrate the superiority of docetaxel and epirubicin vs docetaxel alone as first-line therapy in metastatic breast cancer patients pretreated with adjuvant or neoadjuvant epirubicin. We compared single agent docetaxel 100 mg m(−2) (D) with the combination of docetaxel...
Autores principales: | Pacilio, C, Morabito, A, Nuzzo, F, Gravina, A, Labonia, V, Landi, G, Rossi, E, De Maio, E, Di Maio, M, D'aiuto, G, Botti, G, Normanno, N, Chiodini, P, Gallo, C, Perrone, F, de Matteis, A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361414/ https://www.ncbi.nlm.nih.gov/pubmed/16622454 http://dx.doi.org/10.1038/sj.bjc.6603096 |
Ejemplares similares
-
Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience
por: De Maio, Ermelinda, et al.
Publicado: (2005) -
Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial
por: Nuzzo, Francesco, et al.
Publicado: (2011) -
Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study
por: Frasci, G, et al.
Publicado: (2006) -
Epirubicin
por: Cornish, J., et al.
Publicado: (1988) -
Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial
por: De Maio, Ermelinda, et al.
Publicado: (2007)